KR102696143B1 - 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역 - Google Patents

보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역 Download PDF

Info

Publication number
KR102696143B1
KR102696143B1 KR1020197030684A KR20197030684A KR102696143B1 KR 102696143 B1 KR102696143 B1 KR 102696143B1 KR 1020197030684 A KR1020197030684 A KR 1020197030684A KR 20197030684 A KR20197030684 A KR 20197030684A KR 102696143 B1 KR102696143 B1 KR 102696143B1
Authority
KR
South Korea
Prior art keywords
ser
thr
val
pro
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197030684A
Other languages
English (en)
Korean (ko)
Other versions
KR20190137821A (ko
Inventor
라메쉬 발리가
딘 엔쥐
Original Assignee
아이쥐엠 바이오사이언스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이쥐엠 바이오사이언스 인코포레이티드 filed Critical 아이쥐엠 바이오사이언스 인코포레이티드
Publication of KR20190137821A publication Critical patent/KR20190137821A/ko
Application granted granted Critical
Publication of KR102696143B1 publication Critical patent/KR102696143B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Prostheses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020197030684A 2017-04-07 2018-04-06 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역 Active KR102696143B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483087P 2017-04-07 2017-04-07
US62/483,087 2017-04-07
PCT/US2018/026474 WO2018187702A2 (en) 2017-04-07 2018-04-06 Modified human igm constant regions for modulation of complement-dependent cytolysis effector function

Publications (2)

Publication Number Publication Date
KR20190137821A KR20190137821A (ko) 2019-12-11
KR102696143B1 true KR102696143B1 (ko) 2024-08-21

Family

ID=63713537

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197030684A Active KR102696143B1 (ko) 2017-04-07 2018-04-06 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역

Country Status (11)

Country Link
US (2) US11401337B2 (enExample)
EP (1) EP3607091A4 (enExample)
JP (3) JP2020512820A (enExample)
KR (1) KR102696143B1 (enExample)
CN (1) CN110536900B (enExample)
AU (1) AU2018248336B2 (enExample)
CA (1) CA3055790A1 (enExample)
IL (1) IL268901B2 (enExample)
MX (1) MX2019011986A (enExample)
SG (1) SG11201908051RA (enExample)
WO (1) WO2018187702A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3105250T3 (da) 2014-02-10 2020-09-28 Igm Biosciences Inc Multispecifikke iga-bindingsmolekyler
HUE042829T2 (hu) 2014-04-03 2019-07-29 Igm Biosciences Inc Módosított J-lánc
CA2972990A1 (en) 2015-01-20 2016-07-28 Beatrice Tien-Yi WANG Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
PL3265575T3 (pl) 2015-03-04 2021-11-29 Igm Biosciences, Inc. Cząsteczki wiążące CD20 i ich zastosowania
CA2980751A1 (en) 2015-03-25 2016-09-29 Stephen F. Carroll Multi-valent hepatitis b virus antigen binding molecules and uses thereof
JP6811723B2 (ja) 2015-04-17 2021-01-13 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法
AU2016329197B2 (en) 2015-09-30 2021-01-21 Igm Biosciences, Inc. Binding molecules with modified J-chain
CN108463472A (zh) 2015-09-30 2018-08-28 Igm生物科学有限公司 具有修饰的j-链的结合分子
SG11201809336QA (en) 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
MX2019011986A (es) * 2017-04-07 2019-11-07 Igm Biosciences Inc Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.
CA3091144A1 (en) 2018-03-01 2019-09-06 Igm Biosciences, Inc. Igm fc and j-chain mutations that affect igm serum half-life
AU2019368289A1 (en) * 2018-10-23 2021-04-29 Igm Biosciences, Inc. Multivalent IgM- and IgA-Fc-based binding molecules
BR112022002780A2 (pt) * 2019-08-15 2022-05-10 Igm Biosciences Inc Moléculas de ligação multiméricas imunoestimulatórias
EP4031252A4 (en) * 2019-09-19 2023-09-13 IGM Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
CA3173414A1 (en) 2020-04-22 2021-10-28 Bruce Keyt Pd-1 agonist multimeric binding molecules
GEAP202416592A (en) * 2022-02-03 2024-11-11 Igm Biosciences Inc Anti-cd38 binding molecules and uses thereof
WO2023196995A1 (en) 2022-04-07 2023-10-12 Repertoire Immune Medicines, Inc. T cell receptor multimers and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120316071A1 (en) 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
US20130089547A1 (en) 2011-09-26 2013-04-11 Jn Biosciences Llc Hybrid Constant Regions
WO2015129651A1 (ja) 2014-02-25 2015-09-03 富士レビオ株式会社 改変単量体ＩｇＭ
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256771A (en) 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US20150071948A1 (en) * 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
TW200540186A (en) * 2003-12-25 2005-12-16 Kirin Brewery Mutants of anti-CD40 antibody
AU2005304973A1 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
KR102102111B1 (ko) 2012-02-08 2020-04-20 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄｉｍ 결합 단백질 및 이의 용도
CN105722855B (zh) 2013-09-05 2021-04-23 Igm生物科学股份有限公司 恒定链经修饰的双特异性五价和六价Ig-M抗体
US9416496B2 (en) * 2013-10-16 2016-08-16 Georgia-Pacific Consumer Products Lp Method for reducing the bulk and increasing the density of a tissue product
DK3105250T3 (da) 2014-02-10 2020-09-28 Igm Biosciences Inc Multispecifikke iga-bindingsmolekyler
HUE042829T2 (hu) 2014-04-03 2019-07-29 Igm Biosciences Inc Módosított J-lánc
CA2972990A1 (en) 2015-01-20 2016-07-28 Beatrice Tien-Yi WANG Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
PL3265575T3 (pl) 2015-03-04 2021-11-29 Igm Biosciences, Inc. Cząsteczki wiążące CD20 i ich zastosowania
CA2980751A1 (en) 2015-03-25 2016-09-29 Stephen F. Carroll Multi-valent hepatitis b virus antigen binding molecules and uses thereof
JP6811723B2 (ja) 2015-04-17 2021-01-13 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法
AU2016329197B2 (en) 2015-09-30 2021-01-21 Igm Biosciences, Inc. Binding molecules with modified J-chain
CN108463472A (zh) 2015-09-30 2018-08-28 Igm生物科学有限公司 具有修饰的j-链的结合分子
CN105441455B (zh) * 2015-10-21 2020-08-28 重庆金迈博生物科技有限公司 一种嵌合核酸分子及其在人源化抗体制备中的应用
SG11201809336QA (en) 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF
US20190330374A1 (en) 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
EP3487298A4 (en) 2016-07-20 2020-03-11 IGM Biosciences, Inc. MULTIMERE CD137 / 4-1BB-BINDING MOLECULES AND USES THEREOF
US20190330360A1 (en) 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
MX2019011986A (es) * 2017-04-07 2019-11-07 Igm Biosciences Inc Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.
US20200392239A1 (en) 2018-02-26 2020-12-17 Igm Biosciences, Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
CA3091144A1 (en) 2018-03-01 2019-09-06 Igm Biosciences, Inc. Igm fc and j-chain mutations that affect igm serum half-life
AU2019368289A1 (en) 2018-10-23 2021-04-29 Igm Biosciences, Inc. Multivalent IgM- and IgA-Fc-based binding molecules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120316071A1 (en) 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
US20130089547A1 (en) 2011-09-26 2013-04-11 Jn Biosciences Llc Hybrid Constant Regions
WO2015129651A1 (ja) 2014-02-25 2015-09-03 富士レビオ株式会社 改変単量体ＩｇＭ
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides

Also Published As

Publication number Publication date
CN110536900B (zh) 2024-06-11
US20210147567A1 (en) 2021-05-20
JP2023085503A (ja) 2023-06-20
IL268901B2 (en) 2025-11-01
CA3055790A1 (en) 2018-10-11
AU2018248336A1 (en) 2019-09-26
IL268901B1 (en) 2025-07-01
JP2024177479A (ja) 2024-12-19
EP3607091A4 (en) 2021-01-20
CN110536900A (zh) 2019-12-03
IL268901A (en) 2019-10-31
SG11201908051RA (en) 2019-09-27
WO2018187702A2 (en) 2018-10-11
AU2018248336B2 (en) 2024-10-03
MX2019011986A (es) 2019-11-07
US11401337B2 (en) 2022-08-02
EP3607091A2 (en) 2020-02-12
KR20190137821A (ko) 2019-12-11
US20220340676A1 (en) 2022-10-27
JP2020512820A (ja) 2020-04-30

Similar Documents

Publication Publication Date Title
KR102696143B1 (ko) 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역
KR102745232B1 (ko) IgM 혈청 반감기에 영향을 미치는 IgM Fc 및 J-쇄 돌연변이
JP6793655B2 (ja) Ｃｄ２０結合分子およびその使用方法
US20230203119A1 (en) Immunostimulatory multimeric binding molecules
JP7585305B2 (ja) 多量体の二重特異性抗ｃｄ１２３結合分子及びその使用
US20220372142A1 (en) Multimeric antibodies with enhanced selectivity for cells with high target density
KR20230005228A (ko) Pd-1 효능제 다량체 결합 분자
KR20220050166A (ko) Igm 글리코변이체
KR20230146022A (ko) 항-cd123 결합 분자 및 이의 용도
KR20240139079A (ko) 항-cd38 결합 분자 및 이의 용도
BR112022002897B1 (pt) Anticorpo multimérico e biespecífico e uso do mesmo para tratar leucemia mieloide aguda

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191017

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210330

Comment text: Request for Examination of Application

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230316

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230712

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230316

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230712

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230515

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210813

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210330

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240112

Patent event code: PE09021S01D

PX0701 Decision of registration after re-examination

Patent event date: 20240729

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240813

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240814

End annual number: 3

Start annual number: 1

PG1601 Publication of registration